Here the mechanism by which perifosine induced cell death in and is described. The drug reduced mitochondrial membrane potential and decreased cellular ATP levels while increasing phosphatidylserine externalization. Perifosine did not increase membrane permeabilization. We also found that the drug inhibited the phosphorylation of Akt in the parasites. These results highlight the potential use of perifosine as an alternative to miltefosine against .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365646 | PMC |
| http://dx.doi.org/10.1128/AAC.02127-16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-Dose Perifosine, a Phase II Phospholipid Akt Inhibitor, Selectively Sensitizes Drug-Resistant ABCB1-Overexpressing Cancer Cells.
Biomol Ther (Seoul)
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Article Synopsis
- * Our experiments included cytotoxicity assays on various cancer cell lines, revealing that perifosine selectively sensitized P-gp-overexpressing MCF-7/ADR and KBV20C cells, unlike other tested Akt inhibitors which were more effective on non-resistant cells.
- * The mechanism behind perifosine's action involved increased apoptosis and cell cycle arrest in resistant MCF-7/ADR cells, yet it did not significantly inhibit P-gp activity, indicating that the drug
Combination of Gene Therapy and Chemotherapy in a New Targeted Hybrid Nanosystem to Hepatocellular Carcinoma.
Int J Nanomedicine
November 2024
CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Purpose: Hepatocellular carcinoma is the most frequent liver cancer and constitutes one of the main causes of cancer mortality. The combination of targeted therapy drugs, such as selumetinib and perifosine that inhibit cell signaling pathways involved in cell survival and proliferation, with the expression of tumor suppressor transgenes, such as PTEN, may result in an efficient therapeutic approach against HCC. Thus, the main objective of this work was to develop a new lipid-polymer hybrid nanosystem (HNP), composed of a PLGA core coated with a pH-sensitive lipid bilayer functionalized with the targeting ligand GalNAc, in order to specifically and efficiently deliver this novel combination of therapeutic agents in HCC cells.
View Article and Find Full Text PDFThe combination of temozolomide and perifosine synergistically inhibit glioblastoma by impeding DNA repair and inducing apoptosis.
Cell Death Discov
July 2024
Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361102, China.
Temozolomide (TMZ) is widely utilized as the primary chemotherapeutic intervention for glioblastoma. However, the clinical use of TMZ is limited by its various side effects and resistance to chemotherapy. The present study revealed the synergistic inhibition of glioblastoma through the combined administration of TMZ and perifosine.
View Article and Find Full Text PDFTargeting the RAS upstream and downstream signaling pathway for cancer treatment.
Eur J Pharmacol
September 2024
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh. Electronic address:
Cancer often involves the overactivation of RAS/RAF/MEK/ERK (MAPK) and PI3K-Akt-mTOR pathways due to mutations in genes like RAS, RAF, PTEN, and PIK3CA. Various strategies are employed to address the overactivation of these pathways, among which targeted therapy emerges as a promising approach. Directly targeting specific proteins, leads to encouraging results in cancer treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!